Grey Wolf is a clinical-stage, UK- and Australia-based drug discovery and development company spearheading a new therapeutic strategy based on a first-of-its-kind approach to antigen modulation. The company’s innovative technology is centered on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a central role in the antigen presentation pathway. The company is leveraging its leadership in the area of ERAP inhibition and antigen modulation to advance novel therapeutic approaches to address the source of immune dysfunction in oncology and autoimmunity.
Grey Wolf’s lead development candidate, GRWD5769, is a potent and selective oral ERAP1 inhibitor that has shown the potential to elicit a powerful and differentiated immune response against tumours. The compound is currently the focus of an ongoing Phase 1/2 clinical trial in a range of solid tumour types. A second ERAP1 inhibitor, GRWD0715, is advancing through preclinical development as a potential treatment for autoimmune disease. The company is also leveraging its leadership in neoantigen creation with an ERAP2 drug discovery program and by therapeutically targeting novel ERAP1 inhibitor-generated cancer antigens with MHC Class I directed therapies, such as soluble T cell receptor (TCR) and TCR mimic bispecifics.
In these efforts, the company is working with leading academic and commercial drug discovery and development partners. The core team is strengthened by a network of collaborations with experts in immuno-oncology, autoimmunity, antigen presentation and drug discovery across world leading academic institutions, including The University of Oxford and Monash University.
Grey Wolf was founded in 2017 by experienced industry professionals; Peter Joyce (CEO; previously at Vertex Pharmaceuticals) and Tom McCarthy (non-executive chairman; former president and CEO of Spinifex Pharmaceuticals).
OUR SCIENCE
Our first-of-there-kind oral ERAP inhibitors allow for the upregulation and downregulation of immune cell activity to achieve specific therapeutic outcomes across various immunologically-driven diseases. Our initial focus lies in immuno-oncology, where we have advanced an ERAP1 inhibitor into the clinic. Follow-on efforts are advancing a second ERAP1 inhibitor through preclinical development in the area of autoimmune disease.
Find out more >
Collaboration is at the heart of everything we do. We create a safe environment for constructive, productive and passionate conversations to take place around issues that are important. We encourage everyone to contribute positively.
We continuously seek new ideas and innovative ways to ensure we are world leading in all areas. We go deep into any challenge so that we are comfortable taking risks.
We strive to be the best in everything we do. We set high standards ensuring we deliver against agreed outcomes. We think things through thoroughly and are pragmatic in our approach to implement ideas and methodology based on all available information.
We make decisions quickly after considering the options. We execute on our decisions and actions to keep moving forward. We make every day count.
OUR INVESTOR GROUP
At the core of Grey Wolf is a commitment to the discovery and development of first-of-their-kind therapeutics capable of transforming the lives of patients with immunologically-driven diseases. Our experienced scientific team is complemented by a network of collaborations with experts in IO, antigen presentation and drug discovery across world-leading academic institutions and contract research organizations, including University of Oxford, Monash University and Sygnature Discovery. Grey Wolf is pioneering an antigen presentation technology, through ERAP inhibition, for disease-modifying therapies in immuno-oncology and autoimmune diseases. Phase I/II clinical trials for the lead oncology program are ongoing with sites in the UK, Spain and Australia, and the lead autoimmune program is expected to enter the clinic in 2025.